Rocket One Inc.

Rocket One Inc. maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 3.39, indicating strong short-term liquidity coverage. The company holds $4.05 million in cash and equivalents against total liabilities of $1.43 million, resulting in a net cash position that supports ongoing operations despite negative operating cash flow of $3.05 million in Q1 2026. The market capitalization stands at $12.49 million, trading at a price-to-book ratio of 3.0, which reflects investor valuation of intangible assets and future potential rather than current tangible book value.

The company reports significant unprofitability with a net loss of $2.69 million in Q1 2026, resulting in a return on equity of -64.7% and a return on assets of -48.1%. These negative returns are consistent with early-stage biopharma companies that have not yet achieved commercial revenue. The absence of revenue ($0.00) means traditional profitability metrics such as gross margin or operating margin are not applicable, and the company’s economic model depends entirely on successful drug development and future commercialization or partnership milestones.

Rocket One Inc. has no disclosed segment or geographic revenue breakdown, as it generates no revenue from product sales or services. The company’s activities are concentrated in research and development, with expenses primarily driven by clinical trials, regulatory filings, and general corporate overhead. The lack of revenue diversification is typical for pre-revenue pharmaceutical firms, where all operational focus is directed toward advancing pipeline candidates toward regulatory approval.

The company’s growth trajectory is characterized by consistent net losses and negative operating cash flows, with Q1 2026 net loss of $2.69 million compared to $3.48 million in the same period of the prior year. Cash reserves declined from $6.25 million at the end of 2025 to $4.05 million in Q1 2026, reflecting a burn rate of approximately $2.2 million per quarter after accounting for financing proceeds. The company raised $701,484 from common stock issuance in Q1 2026, but this was insufficient to offset operating cash outflows, highlighting the need for continued capital raises to sustain operations.

Key risk factors include substantial doubt about the company’s ability to continue as a going concern, as noted by its independent auditor, and the risk of dilution from future equity offerings. The company faces listing compliance risks on Nasdaq, having traded below the $1.00 minimum bid price for 20 consecutive days, which could trigger delisting proceedings if not resolved within the cure period. Additionally, the company’s reliance on equity financing exposes shareholders to potential dilution, as future capital raises will likely require the issuance of additional shares.

Recent filings highlight the company’s going-concern status and the associated risks to future financing and stock price stability. The Nasdaq listing compliance warning underscores the urgency for the company to either raise its share price above $1.00 or secure a reverse stock split or other corrective action to maintain its exchange listing. No recent news events or transcript observations indicate progress on clinical milestones or partnership announcements that could alter the company’s near-term trajectory.

Operating income -$2.6M.

• ▍Operating income -$2.6M

Operating income -$9.8M.

• ▍Operating income -$9.8M

Operating income -$5.7M.

• ▍Operating income -$5.7M

Operating income -$12.4M.

• ▍Operating income -$12.4M

Operating income -$8.2M.

• ▍Operating income -$8.2M

Operating income -$8.2M.

• ▍Operating income -$8.2M

Operating income -$6.1M.

• ▍Operating income -$6.1M

Operating income -$3.9M.

• ▍Operating income -$3.9M